Skip to Content
Global News Select

ADRs End Higher; BioNTech, AnPac Among Companies Actively Trading

By Kimberly Chin

 

International stocks trading in New York closed higher on Wednesday.

The S&P/BNY Mellon index of American depositary receipts rose 1.6% to 166.45. The European index improved 1.9% to 140.80. The Asian index rose 1.3% to 234.36. The Latin American index increased 1.7% to 213.42. And the emerging-markets index rose 1.3% to 401.66.

BioNTech SE's ADRs rose 5.9% after the company and its partner Pfizer Inc. said Wednesday that their Covid-19 vaccine will be partly produced in South Africa from next year. The deal -- under which the Cape Town-based Biovac Institute will fill vials of the Pfizer-BioNTech vaccine and ready them for shipment -- follows growing pressure from the U.S., Europe and international organizations for drugmakers to do more to tackle global inequities in accessing Covid-19 shots. Biovac will deliver more than 100 million doses annually once its plant is fully operational next year, the companies said.

AnPac Bio-Medical Science Co.'s ADRs jumped 6.3% after the biotechnology company with operations in China and the U.S. said it has agreed to take a minority equity interest of 40% in Advanced Life Therapeutics Co. to perform contract research and development on integrated circuit-based components for medical devices that help treat cancer. AnPac expects to start receiving revenue from this project starting in the third quarter, it said.

Bayer AG's ADRs, which trade over the counter, rose 1.4% after the German conglomerate said Wednesday that its heart-failure treatment, Verquvo, was granted marketing authorization in the European Union.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

(END) Dow Jones Newswires

July 21, 2021 19:00 ET (23:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.